Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1991 3
1992 8
1993 5
1994 4
1996 2
1997 2
1998 3
1999 6
2000 2
2002 2
2003 5
2004 3
2006 3
2007 1
2008 2
2009 5
2010 2
2011 6
2012 6
2013 8
2014 5
2015 3
2016 6
2017 7
2018 3
2019 2
2020 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.
Patterson JC, Varkaris A, Croucher PJP, Ridinger M, Dalrymple S, Nouri M, Xie F, Varmeh S, Jonas O, Whitman MA, Chen S, Rashed S, Makusha L, Luo J, Isaacs JT, Erlander MG, Einstein DJ, Balk SP, Yaffe MB. Patterson JC, et al. Among authors: erlander mg. Cancer Res. 2023 Jan 18;83(2):219-238. doi: 10.1158/0008-5472.CAN-22-1533. Cancer Res. 2023. PMID: 36413141 Free PMC article.
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas.
Affatato R, Chiappa M, Guffanti F, Ricci F, Formenti L, Fruscio R, Jaconi M, Ridinger M, Erlander M, Damia G. Affatato R, et al. Among authors: erlander m. Ther Adv Med Oncol. 2022 May 31;14:17588359221095064. doi: 10.1177/17588359221095064. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35665077 Free PMC article.
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA, Spira AI, Tsai ML, Samuëlsz E, Silberman SL, Erlander M, Wang ES. Zeidan AM, et al. Among authors: erlander m. Clin Cancer Res. 2020 Dec 1;26(23):6132-6140. doi: 10.1158/1078-0432.CCR-20-2586. Epub 2020 Sep 30. Clin Cancer Res. 2020. PMID: 32998961 Clinical Trial.
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers.
Wang X, Li B, Ciotkowska A, Rutz B, Erlander MG, Ridinger M, Wang R, Tamalunas A, Waidelich R, Stief CG, Hennenberg M. Wang X, et al. Among authors: erlander mg. Eur J Pharmacol. 2020 Apr 15;873:172985. doi: 10.1016/j.ejphar.2020.172985. Epub 2020 Feb 1. Eur J Pharmacol. 2020. PMID: 32017934
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel SM, Reckamp KL, Camidge DR, Pérol M, Ou SI, Liu SV, Yu HA, Soria JC, Socinski MA, Mekhail TM, Solomon BJ, Natale RB, Otterson GA, Papadimitrakopoulou V, Langer CJ, Neal JW, Despain D, Yurasov S, Litten JB, Erlander M, Raponi M, Wakelee HA. Goldman JW, et al. Among authors: erlander m. JCO Precis Oncol. 2018 Nov;2:1-13. doi: 10.1200/PO.17.00116. JCO Precis Oncol. 2018. PMID: 35135111
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Jerevall PL, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi AJ, Wu Y, Erlander MG, Zhang Y, Schnabel CA, Goss PE, Horick N, Sgroi DC. Jerevall PL, et al. Among authors: erlander mg. Breast Cancer Res Treat. 2019 Jan;173(2):375-383. doi: 10.1007/s10549-018-5013-6. Epub 2018 Oct 22. Breast Cancer Res Treat. 2019. PMID: 30350269
Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.
Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Chen I, et al. Among authors: erlander mg. Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228650 Free PMC article.
101 results